Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 125

1.

COPD-Therapie in Praxis und Spital: Exazerbationen verhindern, Prognose verbessern.

Barandun J.

Praxis (Bern 1994). 2017 Apr;106(9):465-469. doi: 10.1024/1661-8157/a002659. Review. German. No abstract available.

PMID:
28443715
2.

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD.

Bishwakarma R, Zhang W, Kuo YF, Sharma G.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 31;12:477-486. doi: 10.2147/COPD.S122354. eCollection 2017.

3.

The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.

Edwards SC, Fairbrother SE, Scowcroft A, Chiu G, Ternouth A, Lipworth BJ.

Int J Chron Obstruct Pulmon Dis. 2016 Nov 22;11:2851-2858. eCollection 2016.

4.

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.

Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC.

PMID:
27585384
5.

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related.

Koehorst-Ter Huurne K, Kort S, van der Palen J, van Beurden WJ, Movig KL, van der Valk P, Brusse-Keizer M.

Int J Chron Obstruct Pulmon Dis. 2016 Jul 26;11:1679-88. doi: 10.2147/COPD.S107303. eCollection 2016.

7.

UPLIFT study - understanding potential long-term impacts on function with tiotropium - and sub-analyses. Bibliographic resume of the obtained results.

Callejas González FJ, Genovés Crespo M, Cruz Ruiz J, Godoy Mayoral R, Agustín Martínez FJ, Martínez García AJ, Tárraga López PJ.

Expert Rev Respir Med. 2016 Sep;10(9):1023-33. doi: 10.1080/17476348.2016.1188693. Epub 2016 May 23. Review.

PMID:
27176208
8.

Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.

Medic G, Lindner L, van der Weijden M, Karabis A.

Adv Ther. 2016 Mar;33(3):379-99. doi: 10.1007/s12325-016-0299-4. Epub 2016 Feb 16. Review.

9.
10.

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.

Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 28;10:2055-66. doi: 10.2147/COPD.S90658. eCollection 2015.

11.

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.

Cheyne L, Irvin-Sellers MJ, White J.

Cochrane Database Syst Rev. 2015 Sep 22;(9):CD009552. doi: 10.1002/14651858.CD009552.pub3. Review.

PMID:
26391969
12.

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma.

Evans DJ, Kew KM, Anderson DE, Boyter AC.

Cochrane Database Syst Rev. 2015 Jul 21;(7):CD011437. doi: 10.1002/14651858.CD011437.pub2. Review.

PMID:
26196545
13.

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).

Vogelmeier CF, Asijee GM, Kupas K, Beeh KM.

Adv Ther. 2015 Jun;32(6):537-47. doi: 10.1007/s12325-015-0216-2. Epub 2015 Jun 23.

14.

Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.

Jones PW.

Ther Adv Respir Dis. 2015 Jun;9(3):84-96. doi: 10.1177/1753465815576471. Epub 2015 Mar 22. Review.

PMID:
25801643
15.

ALAT-2014 Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines: questions and answers.

Montes de Oca M, López Varela MV, Acuña A, Schiavi E, Rey MA, Jardim J, Casas A, Tokumoto A, Torres Duque CA, Ramírez-Venegas A, García G, Stirbulov R, Camelier A, Bergna M, Cohen M, Guzmán S, Sánchez E.

Arch Bronconeumol. 2015 Aug;51(8):403-16. doi: 10.1016/j.arbres.2014.11.017. Epub 2015 Jan 14. English, Spanish.

16.

Tiotropium as part of inhaled polytherapy: adherence and associated health-care utilization.

Simon-Tuval T, Maimon N.

Respirology. 2015 Feb;20(2):304-11. doi: 10.1111/resp.12453. Epub 2014 Dec 16.

17.

[Long-term treatment strategy in chronic obstructive pulmonary disease: how to change the course of the disease].

Devillier P, Salvator H, Roche N, Grassin-Delyle S, Naline E, Dorocant S, Neveu H.

Presse Med. 2014 Dec;43(12 Pt 1):1368-80. doi: 10.1016/j.lpm.2014.09.009. Epub 2014 Nov 1. Review. French.

18.

Aclidinium bromide for stable chronic obstructive pulmonary disease.

Ni H, Soe Z, Moe S.

Cochrane Database Syst Rev. 2014 Sep 19;(9):CD010509. doi: 10.1002/14651858.CD010509.pub2. Review.

PMID:
25234126
19.

Use and outcomes associated with long-acting bronchodilators among patients hospitalized for chronic obstructive pulmonary disease.

Lindenauer PK, Shieh MS, Pekow PS, Stefan MS.

Ann Am Thorac Soc. 2014 Oct;11(8):1186-94. doi: 10.1513/AnnalsATS.201407-311OC.

20.

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.

Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D'Andrea P, Fogel R, Banerji D.

Respir Med. 2014 Oct;108(10):1498-507. doi: 10.1016/j.rmed.2014.07.011. Epub 2014 Aug 4.

Supplemental Content

Loading ...
Support Center